leisure time -WSS

leisure time

author：leisure time 2025-09-30 12:57:22 - browse：34

European Medicines Agency Suffers Cyber Attack in Amsterdam — Paulo Amorim / VWPics via AP Images

LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now.

A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year.

The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Readout LOUD podcast: Live from the 2023 STAT Summit

WSS

STAT Readout Newsletter: Biotech news today

Health tech investors get more selective as pandemic boom fades

STAT Summit: How researchers deal with rejection

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

CZI to create biohub to build anti

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

hotspot

leisure time

entertainment

Duchenne breakthrough therapy leaves behind pioneering families

STAT Summit: Meghan O’Rourke on making chronic illness visible

The high cost of giving birth even with insurance

STAT Readout Newsletter: Biotech news today

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

After Optum profits sink, UnitedHealth makes changes

In Memoriam: Notable people who died in 2023

UnitedHealth, Optum discontinue NaviHealth name

Hepatitis C has a cure — but many Americans still lack access to it

STAT Readout: Friday, Oct. 20 biotech updates

Wikipedia

Biden administration begins canceling student loan debt for 804,000 borrowers

Mark Cuban is blaming the wrong people for high drug costs

After Optum profits sink, UnitedHealth makes changes

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: Meghan O’Rourke on making chronic illness visible

Readout LOUD podcast: Live from the 2023 STAT Summit

Wikipedia

focus

focus

hotspot